MTOR and thyroid cancer: MiR-424-5p has been shown to reduce cell viability by modulating the PTEN/PI3K/AKT/mTOR pathway in breast-cancer cells [34], the MAPK pathway in ischemic stroke [35], and the Hippo-signaling pathway in thyroid cancer [36].